Table 2.
Presence of individual symptoms during follow-up in respondents without PPI use
| |
Symptom frequency |
|||
|---|---|---|---|---|
| 0 days | 1 day | 2-3 days | 4-7 days | |
|
Heartburn during the preceding week | ||||
|
Baseline (%) |
25/403 (6.2) |
46/403 (11.4) |
152/403 (37.7) |
180/403(44.7) |
|
4 weeks (%) |
59/403 (14.6) |
84/403 (20.8) |
142/403 (35.2) |
118/403 (29.3) |
|
12 weeks (%) |
23/140 (16.4) |
40/140 (28.6) |
41/140 (29.3) |
36/140 (25.7) |
|
24 weeks (%) |
15/68 (22.1) |
15/68 (22.1) |
23/68 (33.8) |
15/68 (22.1) |
|
Regurgitation during the preceding week | ||||
|
Baseline (%) |
124/403 (30.8) |
136/403 (33.7) |
82/403 (20.3) |
61/403 (19.4) |
|
4 weeks (%) |
135/403 (33.5) |
125/403 (31.0) |
99/403 (24.6) |
44/403 (10.9) |
|
12 weeks (%) |
61/140 (43.6) |
40/140 (28.6) |
26/140 (18.6) |
13/140 (9.3) |
|
24 weeks (%) |
35/68 (51.5) |
20/68 (29.4) |
10/68 (14.7) |
3/68 (4.4) |
|
Sleep disturbance during the preceding week | ||||
|
Baseline (%) |
81/403 (20.1) |
108/403 (26,8) |
136/403 (33.7) |
78/403 (19.4) |
|
4 weeks (%) |
116/403 (28.8) |
96/403 (23.8) |
120/403 (29.8) |
71/403 (17.6) |
|
12 weeks (%) |
49/140 (35.0) |
36/140 (25.7) |
34/140 (24.3) |
21/140 (15.0) |
|
24 weeks (%) |
19/68 (27.9) |
19/68 (27.9) |
21/68 (30.9) |
9/68 (13.2) |
|
OTC use during the preceding week | ||||
|
Baseline (%) |
107/403 (26.6) |
68/403 (16.9) |
117/403 (29.0) |
111/403 (27.5) |
|
4 weeks (%) |
106/403 (26.3) |
70/403 (17.4) |
107/403 (26.6) |
120/403 (29.8) |
|
12 weeks (%) |
39/140 (27.9) |
30/140 (21.4) |
33/140 (23.6) |
38/140 (27.1) |
| 24 weeks (%) | 25/68 (36.8) | 11/68 (16.2) | 16/68 (23.5) | 16/68 (25.3) |
OTC: over-the-counter.